Literature DB >> 17366267

Rodent models of tremor.

Hideto Miwa1.   

Abstract

This review focuses on rodent models of tremor, particularly those induced by pharmacological agents. Harmaline is one of the most frequently used tremor-generating drugs and harmaline-induced tremor is regarded as a model of essential tremor. Harmaline acts on inferior olive neurons, causing enhanced neuronal synchrony and rhythmicity in the olivocerebellar system. In addition, it selectively induces cerebellar Purkinje cell death, speculatively because of excessive glutamate release from nerve terminals of the olivocerebellar system onto Purkinje cells. Systemic administration of cholinomimetics can also produce generalized tremor, and muscarinic receptors on striatal neurons are thought to be the best candidate for the tremor-generating mechanism. On the other hand, dopaminergic neurotoxins, which are used in models of parkinsonism, have yet to be used for experimental analysis of tremor, because tremors induced by dopamine depletion in rodents are less remarkable than those induced by harmaline or cholinomimetics. Recently developed gamma-aminobutyric acid (GABA)(A) receptor alpha-1 subunit knockout mice exhibit postural and kinetic tremors, and clearly reproduce the features of essential tremors. Although from a phenomenological point of view, rodent models of tremor cannot entirely mimic human tremor disorders, they have useful advantages in the analysis of pathophysiological mechanisms underlying tremor. Development of convenient and reproducible methods for evaluating rodent tremor is therefore recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17366267     DOI: 10.1080/14734220601016080

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.648


  56 in total

Review 1.  Stereotactic neurosurgery for tremor.

Authors:  Johannes D Speelman; Richard Schuurman; Rob M A de Bie; Rianne A J Esselink; D Andries Bosch
Journal:  Mov Disord       Date:  2002       Impact factor: 10.338

2.  Concurrent quantification of tremor and depression of locomotor activity induced in rats by harmaline and physostigmine.

Authors:  G Wang; S C Fowler
Journal:  Psychopharmacology (Berl)       Date:  2001-11       Impact factor: 4.530

3.  An investigation of the tremorgenic effects of oxotremorine and tremorine after stereotaxic injection into rat brain.

Authors:  B Cox; D Potkonjak
Journal:  Int J Neuropharmacol       Date:  1969-05

4.  Pharmacology of experimental tremor.

Authors:  P Stern; N Radović; S Buljubasić
Journal:  Nature       Date:  1965-06-19       Impact factor: 49.962

5.  Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.

Authors:  John D Salamone; Brian B Carlson; Clifford Rios; Elizabeth Lentini; Merce Correa; Ania Wisniecki; Adrienne Betz
Journal:  Behav Brain Res       Date:  2005-01-30       Impact factor: 3.332

6.  Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity.

Authors:  R N Kalaria; M J Mitchell; S I Harik
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

7.  Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults.

Authors:  M Gupta; B K Gupta; R Thomas; V Bruemmer; J R Sladek; D L Felten
Journal:  Neurosci Lett       Date:  1986-10-20       Impact factor: 3.046

8.  EMG analysis of harmaline-induced tremor in normal and three strains of mutant mice with Purkinje cell degeneration and the role of the inferior olive.

Authors:  T E Milner; G Cadoret; L Lessard; A M Smith
Journal:  J Neurophysiol       Date:  1995-06       Impact factor: 2.714

9.  Validation of a new computerized system for recording and analysing drug-induced tremor in rats.

Authors:  A de Souza da Fonseca; F R Pereira; R Santos
Journal:  J Pharmacol Toxicol Methods       Date:  2001 Nov-Dec       Impact factor: 1.950

10.  Harmaline-induced tremor. I. Regional metabolic activity as revealed by [14C]2-deoxyglucose in cat.

Authors:  C Batini; C Buisseret-Delmas; M Conrath-Verrier
Journal:  Exp Brain Res       Date:  1981       Impact factor: 1.972

View more
  38 in total

Review 1.  The cerebellum, cerebellar disorders, and cerebellar research--two centuries of discoveries.

Authors:  Mario Manto
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

2.  Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats.

Authors:  Wacław Kolasiewicz; Katarzyna Kuter; Jadwiga Wardas; Krystyna Ossowska
Journal:  J Neural Transm (Vienna)       Date:  2009-06-24       Impact factor: 3.575

Review 3.  Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease?

Authors:  Atbin Djamshidian; Sabine Bernschneider-Reif; Werner Poewe; Andrew J Lees
Journal:  Mov Disord Clin Pract       Date:  2015-10-06

4.  The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease.

Authors:  Zixiu Xiang; Analisa D Thompson; John T Brogan; Michael L Schulte; Bruce J Melancon; Debbie Mi; L Michelle Lewis; Bende Zou; Liya Yang; Ryan Morrison; Tammy Santomango; Frank Byers; Katrina Brewer; Jonathan S Aldrich; Haibo Yu; Eric S Dawson; Min Li; Owen McManus; Carrie K Jones; J Scott Daniels; Corey R Hopkins; Ximin Simon Xie; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2011-12-21       Impact factor: 4.418

5.  Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.

Authors:  James C Barrow; Kenneth E Rittle; Thomas S Reger; Zhi-Qiang Yang; Phung Bondiskey; Georgia B McGaughey; Mark G Bock; George D Hartman; Cuyue Tang; Jeanine Ballard; Yuhsin Kuo; Thomayant Prueksaritanont; Cindy E Nuss; Scott M Doran; Steven V Fox; Susan L Garson; Richard L Kraus; Yuxing Li; Michael J Marino; Valerie Kuzmick Graufelds; Victor N Uebele; John J Renger
Journal:  ACS Med Chem Lett       Date:  2010-02-01       Impact factor: 4.345

6.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

7.  Excitatory Amino acid transporter expression in the essential tremor dentate nucleus and cerebellar cortex: A postmortem study.

Authors:  Jie Wang; Geoffrey C Kelly; William J Tate; Yong-Shi Li; Michelle Lee; Jesus Gutierrez; Elan D Louis; Phyllis L Faust; Sheng-Han Kuo
Journal:  Parkinsonism Relat Disord       Date:  2016-09-06       Impact factor: 4.891

8.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Authors:  Chao Wu; Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2009-05-13       Impact factor: 5.858

Review 9.  Linking Essential Tremor to the Cerebellum: Neurochemical Evidence.

Authors:  Juan Marin-Lahoz; Alexandre Gironell
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

10.  Potential role of CYP2D6 in the central nervous system.

Authors:  Jie Cheng; Yueying Zhen; Sharon Miksys; Diren Beyoğlu; Kristopher W Krausz; Rachel F Tyndale; Aiming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2013-04-25       Impact factor: 1.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.